Unknown

Dataset Information

0

A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer.


ABSTRACT: BACKGROUND:PEP02, also known as MM-398, is a novel nanoliposomal irinotecan that has improved pharmacokinetics and tumour bio-distribution of the free drug. This phase 2 study evaluated PEP02 monotherapy as second-line treatment for pancreatic cancer. METHODS:Patients who had metastatic pancreatic adenocarcinoma, Karnofsky performance status ?70, and had progressed following gemcitabine-based therapy were eligible. Intravenous injection of PEP02 120 mg m(-2) was given every 3 weeks. Simon 2-stage design was used. The primary objective was 3-month survival rate (OS(3-month)). RESULTS:A total of 40 patients were enrolled. The most common severe adverse events included neutropenia, abdominal pain, asthenia, and diarrhoea. Three patients (7.5%) achieved an objective response, with an additional 17 (42.5%) demonstrating stable disease for a minimum of two cycles. Ten (31.3%) of 32 patients with an elevated baseline CA19-9 had a >50% biomarker decline. The study met its primary end point with an OS(3-month) of 75%, with median progression-free survival and overall survival of 2.4 and 5.2 months, respectively. CONCLUSION:PEP02 demonstrates moderate antitumour activity with a manageable side effect profile for metastatic, gemcitabine-refractory pancreatic cancer patients. Given the limited treatment options available to this patient population, a phase 3 trial of PEP02 (MM-398), referred to as NAPOLI-1, is currently underway.

SUBMITTER: Ko AH 

PROVIDER: S-EPMC3749576 | biostudies-literature | 2013 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer.

Ko A H AH   Tempero M A MA   Shan Y-S YS   Su W-C WC   Lin Y-L YL   Dito E E   Ong A A   Wang Y-W YW   Yeh C G CG   Chen L-T LT  

British journal of cancer 20130723 4


<h4>Background</h4>PEP02, also known as MM-398, is a novel nanoliposomal irinotecan that has improved pharmacokinetics and tumour bio-distribution of the free drug. This phase 2 study evaluated PEP02 monotherapy as second-line treatment for pancreatic cancer.<h4>Methods</h4>Patients who had metastatic pancreatic adenocarcinoma, Karnofsky performance status ≥70, and had progressed following gemcitabine-based therapy were eligible. Intravenous injection of PEP02 120 mg m(-2) was given every 3 week  ...[more]

Similar Datasets

| S-EPMC4831286 | biostudies-literature
| S-EPMC5349428 | biostudies-literature
| S-EPMC4821390 | biostudies-literature
| S-EPMC5318973 | biostudies-literature
| S-EPMC5484436 | biostudies-literature
| S-EPMC10461640 | biostudies-literature
| S-EPMC9440135 | biostudies-literature
| S-EPMC2645085 | biostudies-literature
| S-EPMC6304301 | biostudies-literature
| S-EPMC5198948 | biostudies-literature